Inflammatory breast cancer the disease, the biology, the treatment

CA Cancer Journal for Clinicians

Volumn 60, Issue 6, 2010, Pages 351-375

  Robertson, Fredika M ^a   Bondy, Melissa ^a   Yang, Wei ^a   Yamauchi, Hideko ^b   Wiggins, Shannon ^a   Kamrudin, Samira ^a   Krishnamurthy, Savitri ^a   Le Petross, Huong ^a   Bidaut, Luc ^a   Player, Audrey N ^a   Barsky, Sanford H ^c   Woodward, Wendy A ^a   Buchholz, Thomas ^a   Lucci, Anthony ^a   Ueno, Naoto ^a   Cristofanilli, Massimo ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CHEMOKINE RECEPTOR; CISPLATIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; CYTOKINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; PACLITAXEL; PAZOPANIB; PROSTANOID RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHO C GUANOSINE TRIPHOSPHATASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SEMAXANIB; SOMATOMEDIN; TIPIFARNIB; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; WNT INDUCIBLE SIGNALING PROTEIN 3;

ANAMNESIS; ANTINEOPLASTIC ACTIVITY; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST RECONSTRUCTION; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER STEM CELL; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DERMATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG TARGETING; ECHOMAMMOGRAPHY; EPITHELIAL MESENCHYMAL TRANSITION; ETHNIC DIFFERENCE; FAMILY HISTORY; GENE OVEREXPRESSION; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INFLAMMATORY BREAST CANCER; LYMPHANGIOGENESIS; MAMMOGRAPHY; MASTECTOMY; MASTITIS; METASTASIS; MOLECULAR INTERACTION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OVERALL SURVIVAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; REVIEW; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BIOPSY; TUMOR VASCULARIZATION;

BODY MASS INDEX; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BREAST NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; NEOPLASM STAGING; OBESITY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RARE DISEASES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, MAMMARY; UNITED STATES;

EID: 78649359184     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20082     Document Type: Review

References (165)

1. Zucali R, Uslenghi C, Kenda R, Bonadonna G. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 1976;37:1422-1431.
2. Bell C. A system of operative surgery. Hartford, CT: Hale & Homser; 1814
3. Walshe JM, Swain SM. Clinical aspects of inflammatory breast cancer. Breast Dis. 2005;22:35-44.
4. Leitch A. Peau d'orange in acute mammary carcinoma: its cause and diagnostic value. Lancet. 1909;174:861-863.
5. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. Breast AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010:347-369.
6. Saltzstein SL. Clinically occult inflammatory carcinoma of the breast. Cancer. 1974;34:382-388.
7. Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995; 62:382-385.
8. Jardines L, Haffty B, Theriault R. Locally advanced, locally recurrent and metastatic breast cancer. In: Pazdur R, Coia L, Hoskins W, Wagman L, eds. Cancer Management. A Multidisciplinary Approach. 3rd ed. Melville, NY: PRR; 1999:73-88.
9. Rosen PP. Rosen's breast pathology. In: Rosen PP, ed. Inflammatory Carcinoma. Philadelphia: Lippincott Williams & Wilkins; 2001:676-683.
10. Resetkova E. Pathologic aspects of inflammatory breast carcinoma: part 1 Histomorphology and differential diagnosis. Semin Oncol. 2008;35:25-32.
11. Charpin C, Bonnier P, Khouzami A, et al. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res. 1992;12:591-597.
12. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. A pathologic definition. Cancer. 1974;33:1045-1047.
13. Taylor G, Melzer A. Inflammatory cancer of the breast. Am J Cancer. 1938;33:33-49.
14. Lucas FV, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer. 1978;41: 1595-1605.
15. Mourali N, Muenz LR, Tabbane F, Belhassen S, Bahi J, Levine PH. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer. 1980;46:2741-2746.
16. Meyer AC, Dockerty MB, Harrington SW. Inflammatory carcinoma of the breast. Surg Gynecol Obstet. 1948;87:417-424.
17. Amparo RS, Angel CD, Ana LH, et al. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat. 2000;64:269-273.
18. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol. 2003;21:2254-2259.
19. Sabate JM, Gomez A, Torrubia S, et al. Lymphoma of the breast: clinical and radiologic features with pathologic correlation in 28 patients. Breast J. 2002;8:294-304.
20. Tan BB, Marsden JR, Sanders DS. Melanoma erysipeloides: inflammatory metastatic melanoma of the skin. Br J Dermatol. 1993;129:327-329.
21. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005;22:9-23.
22. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99:1335-1339.
23. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-1674.
24. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010 CA: Cancer J Clin, published online July 7 2010. doi:10.3322
25. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005; 97:966-975.
26. Levine PH, Veneroso C. The epidemiology of inflammatory breast cancer. Semin Oncol. 2008;35:11-16.
27. Tabbane F, Muenz L, Jaziri M, Cammoun M, Belhassen S, Mourali N. Clinical and prognostic features of a rapidly progressing breast cancer in Tunisia. Cancer. 1977;40:376-382.
28. Bondy M, Cristofanilli M, El-Zein R, Wiggins S, Lara J, Jackson S. A Progress Review of the Inflammatory Breast Cancer Registry at the University of Texas M.D. Anderson Cancer Center. San Antonio Breast Cancer Symposium. San Antonio, Tex: 2009 Cancer Research February10. 2010 69:2073; doi:10.1158/0008-5472. SABCS-09-2073
29. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol. 1998;16:3731-3735.
30. Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J. 2001; 7:398-404.
31. Choueiri MB, Otrock ZK, Tawil AN, El- Hajj II, El Saghir NS. Inflammatory breast cancer in a male. N Z Med J. 2005;118: U1566.
32. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008; 109:417-426.
33. Chow CK. Imaging in inflammatory breast carcinoma. Breast Dis. 2005;22:45-54.
34. Gunhan-Bilgen I, Ustun EE, Memis A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology. 2002;223:829-838.
35. Yang WT, Ahuja A, Tang A, Suen M, King W, Metreweli C. High resolution sonographic detection of axillary lymph node metastases in breast cancer. J Ultrasound Med. 1996;15:241-246.
36. Vlastos G, Fornage BD, Mirza NQ, et al. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg. 2000;179:446-452.
37. Lee KW, Chung SY, Yang I, et al. Inflammatory breast cancer: imaging findings. Clin Imaging. 2005;29:22-25.
38. Renz DM, Baltzer PA, Bottcher J, et al. Inflammatory breast carcinoma in magnetic resonance imaging a comparison with locally advanced breast cancer. Acad Radiol. 2008;15:209-221.
39. Rieber A, Tomczak RJ, Mergo PJ, Wenzel V, Zeitler H, Brambs HJ. MRI of the breast in the differential diagnosis of mastitis versus inflammatory carcinoma and follow- up. J Comput Assist Tomogr. 1997;21: 128-132.
40. Chen JH, Mehta RS, Nalcioglu O, Su MY. Inflammatory breast cancer after neoadjuvant chemotherapy: can magnetic resonance imaging precisely diagnose the final pathological response? Ann Surg Oncol. 2008;15:3609-3613.
41. Le-Petross HCT, Cristofanilli M, Qing Y, et al. Inflammatory breast cancer: defining breast magnetic resonance imaging features [abstract]. Cancer Res. 2009;69(2 suppl). Abstract 4008.
42. Thukral A, Thomasson DM, Chow CK, et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology. 2007;244:727-735.
43. Belli P, Costantini M, Romani M, Pastore G. Role of magnetic resonance imaging in inflammatory carcinoma of the breast. Rays. 2002;27:299-305.
44. Willson SA, Adam EJ, Tucker AK. Patterns of breast skin thickness In normalmammograms. Clin Radiol. 1982;33:691-693.
45. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat. 2003;78:51-58.
46. Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin NAm. 2006;14:383-389, vii.
47. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777.
48. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007;25:4104-4109.
49. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJRAmJ Roentgenol. 2003; 181:1275-1282.
50. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging. 2001;13:868-875.
51. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
52. Danforth DN Jr, Aloj L, Carrasquillo JA, et al. The role of 18F-FDG-PET in the local/ regional evaluation of women with breast cancer. Breast Cancer Res Treat. 2002;75: 135-146.
53. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2005;35: 84-99.
54. van der Hoeven JJ, Krak NC, Hoekstra OS, et al. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol. 2004;22:1253-1259.
55. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol. 2004;27:407-410.
56. Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DH. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med. 2005;46:1455-1459.
57. Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50:231-238.
58. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245-3251.
59. Imaging as a biomarker: standards for change measurements in therapy. Gaithersburg, Maryland: US Measurement System Workshop, NIST campus; 2006 URL: http://imaging.cancer.gov/reportsand publications/ReportsandPresentations? NIST-Workshop.pdf
60. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806-1814.
61. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695.
62. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med. 1996;37:931-938.
63. Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J. 2006;12: 309-323.
64. Lee JH, Huh YM, Jun YW, et al. Artificially engineered magnetic nanoparticles for ultra- sensitive molecular imaging. Nat Med. 2007;13:95-99.
65. Achilefu S. Lighting up tumors with receptor- specific optical molecular probes. Technol Cancer Res Treat. 2004;3:393-409.
66. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003;63:2723-2727.
67. Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther. 2007;6:1230-1238.
68. Winnard P Jr, Raman V. Real time noninvasive imaging of receptor-ligand interactions in vivo. J Cell Biochem. 2003;90: 454-463.
69. Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-2252.
70. van den Elsen PA, Pol EJD, Viergever, MA. Medical image matching-a review with classification. IEEE Eng Med Biol Mag. 1993;12:26-39.
71. Maintz JB, Viergever MA. A survey of medical image registration. Med Image Anal. 1998;2:1-36.
72. Bankman I. Handbook of Medical Imaging. Vol 2 Medical Image Processing and Analysis. Bellingham, Wash: SPIE; 2000
73. Crum WR, Griffin LD, Hill DL, Hawkes DJ. Zen and the art of medical image registration: correspondence, homology, and quality. Neuroimage. 2003;20:1425-1437.
74. Crum WR, Hartkens T, Hill DL. Non-rigid image registration: theory and practice. Br J Radiol. 2004;77 Spec No 2:S140-S153.
75. Bidaut L. Multisensor imaging and virtual simulation for assessment, diagnosis, therapy planning, and navigation. Simulation & Gaming. 2001;32:370-390.
76. Bidaut L, Akhurst T, Downey RJ. Advanced imaging including PET/CT for cardiothoracic surgery. Semin Thorac Cardiovasc Surg. 2004;16:272-282.
77. Van Laere SJ, Van den Eynden GG, Van der Auwera I, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat. 2006;95:243-255.
78. Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res. 2004;10:6215-6221.
79. Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989;43:201-208.
80. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer. 2007;97:659-669.
81. Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol. 2007;18:1021-1029.
82. Forozan F, Veldman R, Ammerman CA, et al. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer. 1999;81:1328-1334.
83. van Golen KL, Davies S, Wu ZF, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999;5:2511-2519.
84. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60:5832-5838.
85. van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther. 2002;1:575-583.
86. Sparano JA, Moulder S, Kazi A, et al. Phase II trial of tipifarnib plus neoadjuvant doxorubicin- cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res. 2009;15:2942-2948.
87. Kleer CG, Zhang Y, Pan Q, Merajver SD. WISP3 (CCN6) is a secreted tumorsuppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia. 2004;6:179-185.
88. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472-1489.
89. Dawood S, Broglio K, Gonzalez-Angulo AM, et al. Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res. 2008;14:1718-1725.
90. Pollak M. Targeting insulin and insulinlike growth factor signalling in oncology. Curr Opin Pharmacol. 2008;8:384-392.
91. Zha J, O'Brien C, Savage H, et al. Molecular predictors of response to a humanized antiinsulin- like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther. 2009;8:2110-2121.
92. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27:3297-3302.
93. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol. 2009;27:3271-3273.
94. Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 2004;10:7965-7971.
95. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase- 2 gene expression in human breast cancer. Int J Oncol. 1997;10:503-507.
96. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274-284.
97. Robertson FM, Simeone AM, Mazumdar A, et al. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol. 2008;7:299-312.
98. de M Souza CH, Toledo-Piza E, Amorin R, Barboza A, Tobias KM. Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J. 2009;50:506-510.
99. Kurebayashi J, Otsuki T, Tang CK, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer. 1999;79: 707-717.
100. Suzuki T, Fujii A, Ohya J, et al. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP- 412 (AV-412) in mouse xenograft models. Cancer Sci. 2009;100:1526-1531.
101. Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999;59:5079-5084.
102. Kleer CG, van Golen KL, Braun T, Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001;14:458-464.
103. Van den Eynden GG, van der Auwera I, Van Laere S, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and noninflammatory breast cancer. Breast Cancer Res Treat. 2004;85:13-22.
104. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha,betacatenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61:5231-5241.
105. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
106. Alpaugh ML, Barsky SH. Reversible model of spheroid formation allows for high efficiency of gene delivery ex vivo and accurate gene assessment in vivo. Hum Gene Ther. 2002;13:1245-1258.
107. Dong HM, Liu G, Hou YF, et al. Dominant- negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro. J Cancer Res Clin Oncol. 2007;133:83-92.
108. Silvera D, Arju R, Darvishian F, et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol. 2009;11:903-908.
109. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999; 155:739-752.
110. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene. 2003;22:3070-3075.
111. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002;62:560-566.
112. Clemente M, Perez M, Illera J, Pena L. Histological, immunohistological and ultrastructural description of vasculogenic mimicry in canine mammary cancer. [published online ahead of print August7. 2009]. Vet Pathol. PMID: 19666861
113. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007;23:675-699.
114. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253-1270.
115. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008;10:R25.
116. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302-1313.
117. Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/ progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7:e1000121.
118. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype.AmJ Pathol. 2008;173: 561-574.
119. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265-273.
120. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
121. Zhang D, LaFortune TA, Krishnamurthy S, et al. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Res. 2009; 15:6639-6648.
122. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009; 69:7495-7498.
123. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321-329.
124. Baldini E, Gardin G, Evagelista G, Prochilo T, Collecchi P, Lionetto R. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer. 2004;5:358-363.
125. Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92:1775-1782.
126. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004;4:415-
127. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
128. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200-1208.
129. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106:1000-1006.
130. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
131. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
132. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
133. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-3685.
134. Guerin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990;5:131-135.
135. Parton M, Dowsett M, Ashley S, Hills M, Lowe F, Smith IE. High incidence of HER-2 positivity in inflammatory breast cancer. Breast. 2004;13:97-103.
136. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006;24:1831-1838.
137. Van Pelt AE, Mohsin S, Elledge RM, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003;4:348-353.
138. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003;21: 46-53.
139. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 375:377-384.
140. Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis. 2005;22:67-73.
141. Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4:452-461.
142. Curcio LD, Rupp E, Williams WL, et al. Beyond palliative mastectomy in inflammatory breast cancer-a reassessment of margin status. Ann Surg Oncol. 1999;6: 249-254.
143. Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:474-484.
144. Thoms WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:739-745.
145. Arthur DW, Schmidt-Ullrich RK, Friedman RB, et al. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys. 1999;44: 289-296.
146. Gonzalez-Angulo AM, Guarneri V, Gong Y, et al. Downregulation of the cyclindependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin Breast Cancer. 2006;7:326-330.
147. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol. 2009;6:387-394.
148. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F. Defining the molecular biology of inflammatory breast cancer. Semin Oncol. 2008;35:41-50.
149. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib in combination with paclitaxel in patients with newly diagnosed inflammatory breast cancer. J Clin Oncol. In press.
150. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
151. Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis. 2005;8:197-204.
152. Bernstein JA, Mehta R. In vivo responseadapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) -_ weekly carboplatin and albumin-bound paclitaxel (nab- TC)/trastuzumab (H)/bevacizumab (B) in large and inflammatory breast cancer (BC): A phase II study [abstract]. J Clin Oncol. 2007;25:11078. Abstract 11078.
153. Overmoyer B, Fu P, Hoppel C, et al. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res. 2007;13:5862-5868.
154. A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Overexpressing Inflammatory Breast Cancer. February4. 2010 http://www.clinicaltrials. gov/ct2/show/NCT00558103. Accessed June 2 2010
155. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer. 2006;94:1355-1360.
156. Shirakawa K, Kobayashi H, Sobajima J, Hashimoto D, Shimizu A, Wakasugi H. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res. 2003;5:136-139.
157. Kleer CG, Zhang Y, Pan Q, et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. 2004;6: R110-R115.
158. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.
159. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
160. Cohen LH, Pieterman E, van Leeuwen RE, et al. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol. 2000;60: 1061-1068.
161. Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer. This study has been completed. First Received: November12. 2002 Last Updated: January27. 2010 http://www.clinicaltrials.gov/ct2/show/NCT00049114. Accessed November12. 2002
162. Somlo G, Frankel P, Chow W, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004;22:1839-1848.
163. Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer. 1999;81:449-456.
164. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000;47:1191-1200.
165. Pisansky TM, Schaid DJ, Loprinzi CL, Donohue JH, Schray MF, Schomberg PJ. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. AmJ Clin Oncol. 1992;15:376-387.